Literature DB >> 20502173

Drug-induced arrhythmias.

Brian J Barnes1, James M Hollands.   

Abstract

The objective of this review is to characterize the mechanisms, risk factors, and offending pharmacotherapeutic agents that may cause drug-induced arrhythmias in critically ill patients. PubMed, other databases, and citation review were used to identify relevant published literature. The authors independently selected studies based on relevance to the topic. Numerous drugs have the potential to cause drug-induced arrhythmias. Drugs commonly administered to critically ill patients are capable of precipitating arrhythmias and include antiarrhythmics, antianginals, antiemetics, gastrointestinal stimulants, antibacterials, narcotics, antipsychotics, inotropes, digoxin, anesthetic agents, bronchodilators, and drugs that cause electrolyte imbalances and bradyarrhythmias. Drug-induced arrhythmias are insidious but prevalent. Critically ill patients frequently experience drug-induced arrhythmias; however, enhanced appreciation for this adverse event has the potential to improve prevention, treatment, patient safety, and outcomes in this patient population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502173     DOI: 10.1097/CCM.0b013e3181de112a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

1.  Antidepressants and QTc prolongation.

Authors:  Raymond W Lam
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186

Review 2.  [Drug-induced long QT syndrome. Relevancy in intensive care medicine].

Authors:  R Laszlo; S Laszlo; K Kettering; J Schreieck; R Riessen
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-01-19       Impact factor: 0.840

3.  Isoflurane for life-threatening bronchospasm: a 15-year single-center experience.

Authors:  David A Turner; David Heitz; Mehrengise K Cooper; P Brian Smith; John H Arnold; Scot T Bateman
Journal:  Respir Care       Date:  2012-03-13       Impact factor: 2.258

4.  Correlation of geomagnetic activity with implantable cardioverter defibrillator shocks and antitachycardia pacing.

Authors:  Elisa Ebrille; Tomas Konecny; Dana Konecny; Radim Spacek; Paul Jones; Pavel Ambroz; Christopher V DeSimone; Brian D Powell; David L Hayes; Paul A Friedman; Samuel J Asirvatham
Journal:  Mayo Clin Proc       Date:  2015-02       Impact factor: 7.616

Review 5.  Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature.

Authors:  Döndü Üsküdar Cansu; Erdal Bodakçi; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

6.  Mechanisms of drug-induced proarrhythmia in clinical practice.

Authors:  Arkadia Konstantopoulou; Spyros Tsikrikas; Dimitrios Asvestas; Panagiotis Korantzopoulos; Konstantinos P Letsas
Journal:  World J Cardiol       Date:  2013-06-26

7.  A predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues.

Authors:  Celinda M Kofron; Tae Yun Kim; Bum-Rak Choi; Kareen L K Coulombe; Fabiola Munarin; Arvin H Soepriatna; Rajeev J Kant; Ulrike Mende
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

8.  Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study.

Authors:  Matthew J Hafermann; Rocsanna Namdar; Gretchen E Seibold; Robert Lee Page
Journal:  Drug Healthc Patient Saf       Date:  2011-10-03

9.  Sleep-Associated Torsades de Pointes: A Case Report.

Authors:  Guy Carmelli; Ian S deSouza
Journal:  Clin Pract Cases Emerg Med       Date:  2017-01-23

10.  Chinese Herbal Medicine Versus Placebo for the Treatment Of Chronic Obstructive Pulmonary Disease: A Protocol of Systematic Review and Meta-analysis.

Authors:  Chan Xiong; Yu Li; Yan Zeng; Hua Wei; Guang-Tong Zhuang; Lin Li; Li-Hong Zhao; Chen-Yi Li; Er-Qi Qin; Juan-Juan Fu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.